PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT06607627
Recruiting
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/08/2025
Locations: Research Site, Washington, District of Columbia +11 locations
Conditions: Generalized Myasthenia Gravis, gMG
Register for Updates
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
NCT06615375
Recruiting
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/08/2025
Locations: Hope Clinic of Emory University, Atlanta, Georgia +2 locations
Conditions: Shigellosis
Register for Updates
Cervical Spine Focused Treatment for Patients With Persistent Concussion Symptoms and Neck Pain
NCT06616272
Recruiting
Assess the feasibility of recruiting, enrolling and randomizing patients with concussion symptoms and neck pain to receive manual therapy and cervical rehabilitative exercises in addition to standard concussion treatment. In the usual care workflow provided at the participating concussion clinic, cervical spine rehab is not typically introduced until after week 4. The rationale is that neck pain is often a self-limiting condition that may resolve spontaneously, without the need for specific cer... Read More
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
07/08/2025
Locations: UPMC sports medicine, Pittsburgh, Pennsylvania +3 locations
Conditions: Brain Concussion, Neck Pain
Register for Updates
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
NCT06630234
Recruiting
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: HonorHealth, Scottsdale, Arizona +8 locations
Conditions: Gastrointestinal Stromal Tumor (GIST)
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Headlands Research, Scottsdale, Arizona +13 locations
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT06654037
Recruiting
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to treatment (refractory). Abemaciclib, a type of cyclin-dependent kinase inhibitor, blocks certain proteins, which may help keep tumor cells from growing. 5-fluorouracil, a type of antimetabo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California +7 locations
Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA19, Little Rock, Arkansas +91 locations
Conditions: Dravet Syndrome
Register for Updates
Pilot Study of the Entarik System With Advanced Functionality in Health Adults
NCT06660758
Recruiting
In this single-site study, data will be recorded during nasogastric or orogastric placement (and post-pyloric placement) and removal of the Entarik Feeding Tube. Data will also be collected prior to, during, and following the delivery of a meal through the feeding tube.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Gravitas Medical, Inc., Berkeley, California
Conditions: Healthy Adults
Register for Updates
Bone Stimulator for Spondylolysis
NCT06666608
Recruiting
This prospective study aims to investigate the effectiveness of bone stimulator therapy as adjunct treatment of spondylolysis in athletic populations. By evaluating its impact on pain reduction, functional improvement, osseous bony union and return-to-sport time, the investigators seek to provide valuable insights into the role of bone stimulation therapy as a potential treatment modality for this challenging condition.
Gender:
ALL
Ages:
Between 16 years and 40 years
Trial Updated:
07/08/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Spondylolysis, Symptomatic Spondylolysis, Athletes
Register for Updates
Mirikizumab Real World Protocol
NCT06696014
Recruiting
The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: South Denver Gastroenterology, Denver, Colorado +8 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA19, Little Rock, Arkansas +98 locations
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987
Recruiting
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or in combination with cetuximab decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone or in combination with cetuximab * Visit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Mayo Clinic, Phoenix, Phoenix, Arizona +8 locations
Conditions: KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (colorectal Cancer)
Register for Updates